No headlines found.
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Thu, 12-Mar 4:05 PM ET)
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. Its flagship program is OKI-219, a selective PI3KaH1047R inhibitor. The Company operates in one operating segment: clinical research.
Onkure Therapeutics - Class A trades on the NASDAQ stock market under the symbol OKUR.
As of March 24, 2026, OKUR stock price was flat at $3.98 with 154,123 million shares trading.
OKUR has a beta of 1.45, meaning it tends to be more sensitive to market movements. OKUR has a correlation of 0.09 to the broad based SPY ETF.
OKUR has a market cap of $54.42 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that OKUR belongs to (by Net Assets): VTI, VXF, IWC, AVTM.
OKUR has underperformed the market in the last year with a return of -21.2%, while SPY returned +17.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in OKUR shares. However, OKUR has outperformed the market in the last 3 month and 2 week periods, returning +40.6% and +17.1%, while SPY returned -4.8% and -3.4%, respectively. This indicates OKUR has been having a stronger performance recently.
OKUR support price is $3.71 and resistance is $4.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OKUR shares will trade within this expected range on the day.
